Skip to main content
Top
Published in: Annals of Hematology 9/2019

01-09-2019 | Thalassemia | Original Article

miR-144 regulates oxidative stress tolerance of thalassemic erythroid cell via targeting NRF2

Authors: Kanitta Srinoun, Nuankanya Sathirapongsasuti, Kittiphong Paiboonsukwong, Somporn Sretrirutchai, Malai Wongchanchailert, Suthat Fucharoen

Published in: Annals of Hematology | Issue 9/2019

Login to get access

Abstract

Thalassemia has a high prevalence in Thailand. Oxidative damage to erythroid cells is known to be one of the major etiologies in thalassemia pathophysiology. Oxidative stress status of thalassemia is potentiated by the heme, nonheme iron, and free iron resulting from imbalanced globin synthesis. In addition, levels of antioxidant proteins are reduced in α-thalassemia and β-thalassemia erythrocytes. However, the primary molecular mechanism for this phenotype remains unknown. Our study showed a high expression of miR-144 in β- and α-thalassemia. An increased miR-144 expression leads to decreased expression of nuclear factor erythroid 2-related factor 2 (NRF2) target, especially in α-thalassemia. In α-thalassemia, miR-144 and NRF2 target are associated with glutathione level and anemia severity. To study the effect of miR-144 expression, the gain-loss of miR-144 expression was performed by miR inhibitor and mimic transfection in the erythroblastic cell line. This study reveals that miR-144 expression was upregulated, whereas NRF2 expression and glutathione levels were decreased in comparison with the untreated condition after miR mimic transfection, while the reduction of miR-144 expression contributed to the increased NRF2 expression and glutathione level compared with the untreated condition after miR inhibitor transfection. Moreover, miR-144 overexpression leads to significantly increased sensitivity to oxidative stress at indicated concentrations of hydrogen peroxide (H2O2) and rescued by miR-144 inhibitor. Taken together, our findings suggest that dysregulation of miR-144 may play a role in the reduced ability of erythrocyte to deal with oxidative stress and increased RBC hemolysis susceptibility especially in thalassemia.
Literature
1.
go back to reference Yuan J, Bunyaratvej A, Fucharoen S, Fung C, Shinar E, Schrier SL (1995) The instability of the membrane skeleton in thalassemic red blood cells. Blood 86(10):3945–3950PubMed Yuan J, Bunyaratvej A, Fucharoen S, Fung C, Shinar E, Schrier SL (1995) The instability of the membrane skeleton in thalassemic red blood cells. Blood 86(10):3945–3950PubMed
2.
go back to reference Advani R, Rubin E, Mohandas N, Schrier SL (1992) Oxidative red blood cell membrane injury in the pathophysiology of severe mouse beta-thalassemia. Blood 79(4):1064–1067PubMed Advani R, Rubin E, Mohandas N, Schrier SL (1992) Oxidative red blood cell membrane injury in the pathophysiology of severe mouse beta-thalassemia. Blood 79(4):1064–1067PubMed
3.
go back to reference Advani R, Sorenson S, Shinar E, Lande W, Rachmilewitz E, Schrier SL (1992) Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia. Blood 79(4):1058–1063PubMed Advani R, Sorenson S, Shinar E, Lande W, Rachmilewitz E, Schrier SL (1992) Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia. Blood 79(4):1058–1063PubMed
5.
go back to reference Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW (1984) Hemoglobin. A biologic Fenton reagent. J Biol Chem 259(23):14354–14356PubMed Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW (1984) Hemoglobin. A biologic Fenton reagent. J Biol Chem 259(23):14354–14356PubMed
7.
go back to reference Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A (2003) Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 338(1–2):79–86CrossRefPubMed Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A (2003) Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 338(1–2):79–86CrossRefPubMed
8.
go back to reference Meral A, Tuncel P, Surmen-Gur E, Ozbek R, Ozturk E, Gunay U (2000) Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr Hematol Oncol 17(8):687–693CrossRefPubMed Meral A, Tuncel P, Surmen-Gur E, Ozbek R, Ozturk E, Gunay U (2000) Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr Hematol Oncol 17(8):687–693CrossRefPubMed
9.
go back to reference Cheng ML, Ho HY, Tseng HC, Lee CH, Shih LY, Chiu DT (2005) Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br J Haematol 128(1):119–127CrossRefPubMed Cheng ML, Ho HY, Tseng HC, Lee CH, Shih LY, Chiu DT (2005) Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br J Haematol 128(1):119–127CrossRefPubMed
10.
go back to reference Chiou SS, Tsao CJ, Tsai SM, Wu YR, Liao YM, Lin PC, Tsai LY (2014) Metabolic pathways related to oxidative stress in patients with hemoglobin h disease and iron overload. J Clin Lab Anal 28(4):261–268CrossRefPubMedPubMedCentral Chiou SS, Tsao CJ, Tsai SM, Wu YR, Liao YM, Lin PC, Tsai LY (2014) Metabolic pathways related to oxidative stress in patients with hemoglobin h disease and iron overload. J Clin Lab Anal 28(4):261–268CrossRefPubMedPubMedCentral
12.
14.
go back to reference Siow RC, J Forman H (2013) Redox regulation of microRNAs in health and disease. Free Radic Biol Med 64:1–3CrossRefPubMed Siow RC, J Forman H (2013) Redox regulation of microRNAs in health and disease. Free Radic Biol Med 64:1–3CrossRefPubMed
16.
go back to reference Sangokoya C, Telen MJ, Chi JT (2010) microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116(20):4338–4348CrossRefPubMedPubMedCentral Sangokoya C, Telen MJ, Chi JT (2010) microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116(20):4338–4348CrossRefPubMedPubMedCentral
17.
go back to reference Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275(21):16023–16029CrossRefPubMed Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275(21):16023–16029CrossRefPubMed
18.
go back to reference Motohashi H, Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10(11):549–557CrossRefPubMed Motohashi H, Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10(11):549–557CrossRefPubMed
19.
go back to reference Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46(4):443–453CrossRefPubMed Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46(4):443–453CrossRefPubMed
20.
go back to reference Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313–322CrossRefPubMed Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313–322CrossRefPubMed
21.
go back to reference Chan JY, Kwong M (2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta 1517(1):19–26CrossRefPubMed Chan JY, Kwong M (2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta 1517(1):19–26CrossRefPubMed
22.
go back to reference Kitamuro T, Takahashi K, Ogawa K, Udono-Fujimori R, Takeda K, Furuyama K, Nakayama M, Sun J, Fujita H, Hida W, Hattori T, Shirato K, Igarashi K, Shibahara S (2003) Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem 278(11):9125–9133CrossRefPubMed Kitamuro T, Takahashi K, Ogawa K, Udono-Fujimori R, Takeda K, Furuyama K, Nakayama M, Sun J, Fujita H, Hida W, Hattori T, Shirato K, Igarashi K, Shibahara S (2003) Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem 278(11):9125–9133CrossRefPubMed
23.
go back to reference Lee JM, Chan K, Kan YW, Johnson JA (2004) Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia. Proc Natl Acad Sci U S A 101(26):9751–9756CrossRefPubMedPubMedCentral Lee JM, Chan K, Kan YW, Johnson JA (2004) Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia. Proc Natl Acad Sci U S A 101(26):9751–9756CrossRefPubMedPubMedCentral
24.
go back to reference Kawatani Y, Suzuki T, Shimizu R, Kelly VP, Yamamoto M (2011) Nrf2 and selenoproteins are essential for maintaining oxidative homeostasis in erythrocytes and protecting against hemolytic anemia. Blood 117(3):986–996CrossRefPubMed Kawatani Y, Suzuki T, Shimizu R, Kelly VP, Yamamoto M (2011) Nrf2 and selenoproteins are essential for maintaining oxidative homeostasis in erythrocytes and protecting against hemolytic anemia. Blood 117(3):986–996CrossRefPubMed
25.
go back to reference Srinoun K, Svasti S, Chumworathayee W, Vadolas J, Vattanaviboon P, Fucharoen S, Winichagoon P (2009) Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice. Haematologica 94(9):1211–1219CrossRefPubMedPubMedCentral Srinoun K, Svasti S, Chumworathayee W, Vadolas J, Vattanaviboon P, Fucharoen S, Winichagoon P (2009) Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice. Haematologica 94(9):1211–1219CrossRefPubMedPubMedCentral
26.
go back to reference Amer J, Goldfarb A, Fibach E (2004) Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 60(1):73–80CrossRefPubMed Amer J, Goldfarb A, Fibach E (2004) Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 60(1):73–80CrossRefPubMed
27.
go back to reference Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E (2006) Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 132(1):108–113CrossRefPubMed Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E (2006) Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 132(1):108–113CrossRefPubMed
28.
29.
go back to reference Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, Cam MC, Miller JL (2007) The human reticulocyte transcriptome. Physiol Genomics 30:172–178CrossRefPubMed Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, Cam MC, Miller JL (2007) The human reticulocyte transcriptome. Physiol Genomics 30:172–178CrossRefPubMed
30.
go back to reference Wilson MC, Trakarnsanga K, Heesom KJ, Cogan N, Green C, Toye AM, Parsons SF, Anstee DJ, Frayne J (2016) Comparison of the proteome of adult and cord erythroid cells, and changes in the proteome following reticulocyte maturation. Mol Cell Proteomics 15(6):1938–1946CrossRefPubMedPubMedCentral Wilson MC, Trakarnsanga K, Heesom KJ, Cogan N, Green C, Toye AM, Parsons SF, Anstee DJ, Frayne J (2016) Comparison of the proteome of adult and cord erythroid cells, and changes in the proteome following reticulocyte maturation. Mol Cell Proteomics 15(6):1938–1946CrossRefPubMedPubMedCentral
31.
go back to reference Li B, Zhu X, Ward CM, Starlard-Davenport A, Takezaki M, Berry A, Ward A, Wilder C, Neunert C, Kutlar A, Pace BS (2019) MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease. Exp Hematol 70:85–96CrossRefPubMed Li B, Zhu X, Ward CM, Starlard-Davenport A, Takezaki M, Berry A, Ward A, Wilder C, Neunert C, Kutlar A, Pace BS (2019) MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease. Exp Hematol 70:85–96CrossRefPubMed
32.
go back to reference Zhou C, Zhao L, Zhenga J (2017) MicroRNA-144 modulates oxidative stress tolerance in SH-SY5Y cells by regulating nuclear factor erythroid 2-related factor 2-glutathione axis. Neurosci Lett 655:21–27CrossRefPubMed Zhou C, Zhao L, Zhenga J (2017) MicroRNA-144 modulates oxidative stress tolerance in SH-SY5Y cells by regulating nuclear factor erythroid 2-related factor 2-glutathione axis. Neurosci Lett 655:21–27CrossRefPubMed
Metadata
Title
miR-144 regulates oxidative stress tolerance of thalassemic erythroid cell via targeting NRF2
Authors
Kanitta Srinoun
Nuankanya Sathirapongsasuti
Kittiphong Paiboonsukwong
Somporn Sretrirutchai
Malai Wongchanchailert
Suthat Fucharoen
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Keyword
Thalassemia
Published in
Annals of Hematology / Issue 9/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03737-4

Other articles of this Issue 9/2019

Annals of Hematology 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.